Search research articles
Contact Us
Filters
Showing results (11-20 of 55) with videos related to
Page
of 6
Sort By:
Neoreviews
|
November 30, 2022
Fetal Hepatomegaly
Jina Park, Devlynne Sasha Ondusko, Bill H Chang, et al.
Oncogene
|
June 1, 2018
Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL
Marilynn Chow, Lina Gao, Jason D MacManiman, et al.
Cancer Cell
|
November 17, 2012
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia
Vincent T Bicocca, Bill H Chang, Behzad Kharabi Masouleh, et al.
Genome Medicine
|
November 30, 2013
Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine
Daniel Bottomly, Peter A Ryabinin, Jeffrey W Tyner, et al.
Genome Research
|
May 26, 2012
Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia
Tyrone Ryba, Dana Battaglia, Bill H Chang, et al.
Pediatric Hematology and Oncology
|
December 1, 2017
Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group
Deepa Bhojwani, Michael J Burke, Terzah Horton, et al.
EMBO Reports
|
July 4, 2019
Extracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche
Sherif Abdelhamed, John T Butler, Ben Doron, et al.
Pediatric Blood & Cancer
|
July 20, 2024
Clonally related benign cephalic histiocytosis, histiocytic sarcoma, and T-cell acute lymphoblastic leukemia: Expanding the spectrum of histiocytic transdifferentiation
J Connor Thellman, Milie M Fang, Tanaya Neff, et al.
British Journal of Haematology
|
February 4, 2012
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study
Bill H Chang, Stephanie G Willis, Linda Stork, et al.
Blood
|
September 8, 2020
Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL
Jessica T Leonard, Yoko Kosaka, Pavani Malla, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 55) with videos related to
Sort By:
Page
of 6
Neoreviews
|
November 30, 2022
Fetal Hepatomegaly
Jina Park, Devlynne Sasha Ondusko, Bill H Chang, et al.
Oncogene
|
June 1, 2018
Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL
Marilynn Chow, Lina Gao, Jason D MacManiman, et al.
Cancer Cell
|
November 17, 2012
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia
Vincent T Bicocca, Bill H Chang, Behzad Kharabi Masouleh, et al.
Genome Medicine
|
November 30, 2013
Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine
Daniel Bottomly, Peter A Ryabinin, Jeffrey W Tyner, et al.
Genome Research
|
May 26, 2012
Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia
Tyrone Ryba, Dana Battaglia, Bill H Chang, et al.
Pediatric Hematology and Oncology
|
December 1, 2017
Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group
Deepa Bhojwani, Michael J Burke, Terzah Horton, et al.
EMBO Reports
|
July 4, 2019
Extracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche
Sherif Abdelhamed, John T Butler, Ben Doron, et al.
Pediatric Blood & Cancer
|
July 20, 2024
Clonally related benign cephalic histiocytosis, histiocytic sarcoma, and T-cell acute lymphoblastic leukemia: Expanding the spectrum of histiocytic transdifferentiation
J Connor Thellman, Milie M Fang, Tanaya Neff, et al.
British Journal of Haematology
|
February 4, 2012
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study
Bill H Chang, Stephanie G Willis, Linda Stork, et al.
Blood
|
September 8, 2020
Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL
Jessica T Leonard, Yoko Kosaka, Pavani Malla, et al.
Page
of 6